Info@ThinkPinkRocks.com

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

Link:
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Share

Leave a Reply